Summary Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.
This report includes Medidata Solutions, Inc.'s contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.
The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Medidata Solutions, Inc.. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.
Key Findings Marketlines' Medidata Solutions, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Medidata Solutions, Inc. since January 2007.
Synopsis - Provides intelligence on Medidata Solutions, Inc.'s M&A, strategic partnerships and alliances, capital raising and private equity transactions.
- Detailed reports of various financial transactions undertaken by Medidata Solutions, Inc. and its subsidiaries since 2007.
- Information about key financial and legal advisors for Medidata Solutions, Inc.'s financial deals transactions.
- Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity.
Reasons To Buy - Access comprehensive financial deals data along with charts and graph covering M&A, private equity, and partnerships and alliances.
- Form an independent opinion about Medidata Solutions, Inc.’s growth strategies through the organic and inorganic activities undertaken since 2007.
- Track your competitors’ business structure and growth strategies.
Key Highlights This report includes Medidata Solutions, Inc.'s contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.
The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Medidata Solutions, Inc.. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.
Our reports have been used by over 10K customers, including:
KEY FINDINGS The global irritable bowel syndrome treatment market is predicted to grow with a CAGR of 7.25%, during the forecast period of 2021 to 2028. The market growth is mainly fueled by factors like, the rising prevalence of gastrointestinal ailments, the increasing number of FDA approvals and drug developments, the...
The North America organoids market is expected to reach US$ 1,406.47 million by 2027 from US$ 291.39 million in 2019. The market is anticipated to grow at a CAGR of 21.7% from 2020 to 2027. Growth of the North America organoids market is attributed to emergence of three-dimensional (3D) organoids and rise in investments in research. However,...
The comprehensive 2,400 page research study on COVID-19 therapeutic and vaccine pipeline candidates, completed, ongoing and planned clinical trials across phases, countries, companies and institutes/hospitals. The global COVID-19 market size outlook remains robust driven by huge potential for administration to 2 billion populations,...
Global Glycobiology Market, By Product (Enzymes, Instruments, Reagents and Kits), By Application (Drug Discovery, Disease Diagnostics, Virology, Cell Biology, Oncology, Others), By End User (Research Institutes, Diagnostic Centers, Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Others), By Region, Competition,...
Report Scope: The scope of the report includes an overview of the global market for nanoparticles in biotechnology, drug development and drug delivery, and analyses of global market trends, using 2019 as the base year and forecasting 2020 through 2025 with compound annual growth rate (CAGR) projections. The report...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the artificial intelligence (AI) in drug discovery market are IBM Corporation, Microsoft, Atomwise Inc., Deep Genomics, Cloud Pharmaceuticals, Insilico Medicine, Benevolent AI, Exscientia, Cyclica, and BIOAGE. The global artificial intelligence (AI) in drug discovery market is expected to decline from $0.37 billion...
20s Proteasome - Pipeline Review, H2 2020
Summary
According to the recently published report ’20s Proteasome - Pipeline Review, H2 2020’; 20s Proteasome pipeline Target constitutes close to 9 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
20s...
The Asia Pacific medical writing market is expected to reach US$ 983.51 million by 2027 from US$ 560.59 million in 2019; it is anticipated to grow at a CAGR of 7.3% during 2020–2027. The growth of Asia Pacific medical writing market is driven by increasing number of market players and growing government support in the healthcare sector....
The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021 report. The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option...
The global high-throughput screening market size is projected to reach USD 26.4 billion by 2025 from USD 15.3 billion in 2020, at a CAGR of 11.5% during the forecast period. The growth in this market is primarily attributed to increasing R&D spending by pharmaceutical & biotechnology companies, technological advancements in high-throughput...
Drug Development
Cell Therapy
United States
World
North America
APAC
Europe
Pharmaceutical R&D Expenditure
Gross Domestic Expenditure On R&D
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.